A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.-论文-万方医学网

作者： Naval,Daver ^[1] ; Yanis,Boumber ^[2] ; Hagop,Kantarjian ^[1] ; Farhad,Ravandi ^[1] ; Jorge,Cortes ^[1] ; Michael E,Rytting ^[1] ; Jitesh D,Kawedia ^[3] ; Jordan,Basnett ^[4] ; Kirk S,Culotta ^[5] ; Zhihong,Zeng ^[1] ; Hongbo,Lu ^[1] ; Mary Ann,Richie ^[1] ; Rebecca,Garris ^[1] ; Lianchun,Xiao ^[6] ; Wenbin,Liu ^[7] ; Keith A,Baggerly ^[7] ; Elias,Jabbour ^[1] ; Susan,O'Brien ^[1] ; Jan,Burger ^[1] ; Linda J,Bendall ^[4] ; Deborah,Thomas ^[8] ; Marina,Konopleva ^[8]

作者单位： Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[1] Hematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[2] Department of Pharmacy Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[3] Center for Cancer Research, Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia. ^[4] Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[5] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[6] Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[7] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. mkonople@mdanderson.org debthomas@mdanderson.org. ^[8]

主题词青少年(Adolescent);成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);儿童(Child);环磷酰胺(Cyclophosphamide);地塞米松(Dexamethasone);多柔比星(Doxorubicin);药物监测(Drug Monitoring);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);肿瘤, 残余(Neoplasm, Residual);前体细胞淋巴母细胞白血病淋巴瘤(Precursor Cell Lymphoblastic Leukemia-Lymphoma);蛋白激酶抑制剂(Protein Kinase Inhibitors);复发(Recurrence);信号传导(Signal Transduction);存活率分析(Survival Analysis);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases);治疗结果(Treatment Outcome);长春新碱(Vincristine);青年人(Young Adult)

DOI 10.1158/1078-0432.CCR-14-2888

PMID 25724525

发布时间 2021-12-03

检索历史清除

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除